XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
Jonsson Comprehensive Cancer Center
Novartis
H. Lee Moffitt Cancer Center and Research Institute
University of Southern California
DEKA Biosciences
Checkpoint Therapeutics, Inc.